Skip to main content

OPTIMIZACION DE UNA PLATAFORMA DE VECTORES NO VIRALES BASADOS EN NIOSOMAS FUNCIONALIZADOS CON NANODIAMANTES PARA TERAPIA GENICA EN FIBROSIS QUISTICA

PID2019-106199RB-C21

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSIDAD DEL PAIS VASCO EUSKAL HERRIKO UNIBERTSITATEA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Non-viral mediated gene therapy in human cystic fibrosis airway epithelial cells recovers chloride channel functionality

  • Sainz-Ramos, Myriam
  • Villate-Beitia, Ilia
  • Gallego, Idoia
  • Qtaish, Nuseibah A. L.
  • López-Méndez, Tania Belén
  • Eritja Casadellà, Ramón
  • Grijalvo, Santiago
  • Puras, Gustavo
  • Pedraz, José Luís
Gene therapy strategies based on non-viral vectors are currently considered as a promising therapeutic option for the treatment of cystic fibrosis (CF), being liposomes the most commonly used gene carriers. Niosomes offer a powerful alternative to liposomes due to their higher stability and lower cytotoxicity, provided by their non-ionic surfactant and helper components. In this work, a three-formulation screening is performed, in terms of physicochemical and biological behavior, in CF patient derived airway epithelial cells. The most efficient niosome formulation reaches 28% of EGFP expressing live cells and follows caveolae-mediated endocytosis. Transfection with therapeutic cystic fibrosis transmembrane conductance regulator (CFTR) gene results in 5-fold increase of CFTR protein expression in transfected versus non-transfected cells, which leads to 1.5-fold increment of the chloride channel functionality. These findings highlight the relevance of niosome-based systems as an encouraging non-viral gene therapy platform with potential therapeutic benefits for CF., Authors wish to thank: ICTS “NANBIOSIS”, specifically the Drug Formulation Unit (U10) of the CIBER in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) for the intellectual and technical assistance; SGIker (UPV/EHU) for technical and human support; the Department of Education, University and Research of the Basque Country Government (Consolidated Groups, IT907-16), the Spanish Ministry of Science and Innovation (Grant PID2019-106199RB-C21); the Cystic Fibrosis Association of the Basque Country; the Unit of Viral Infections and Comparative Pathology at the University of Lyon 1 and UK Cystic Fibrosis Gene Therapy Consortium for kindly providing the gene constructs used in this work: pEGFP-CFTR and pGM169, respectively. M.S.R. thanks the University of the Basque Country (UPV/EHU) for the granted pre-doctoral fellowship (PIF17/79). I.V.B. thanks the University of the Basque Country (UPV/EHU) for the granted post-doctoral fellowship (ESPDOC19/47). Funding source declaration This work was supported by the University of Basque Country (UPV/EHU) (pre-doctoral grant PIF17/79 and post-doctoral grant ESPDOC19/47), the Department of Education, University and Research of the Basque Country Government (Consolidated Groups, IT907-16), the Spanish Ministry of Science and Innovation (Grant PID2019-106199RB-C21); and the Cystic Fibrosis Association of the Basque Country., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Correlation between Biophysical Properties of Niosomes Elaborated with Chloroquine and Different Tensioactives and Their Transfection Efficiency

  • Sainz-Ramos, Myriam
  • Villate-Beitia, Ilia
  • Gallego, Idoia
  • AL Qtaish, Nuseibah
  • Menéndez, Margarita
  • Lagartera, Laura
  • Grijalvo, Santiago
  • Eritja Casadellà, Ramón
  • Puras, Gustavo
  • Pedraz, José Luís
Lipid nanocarriers, such as niosomes, are considered attractive candidates for non-viral gene delivery due to their suitable biocompatibility and high versatility. In this work, we studied the influence of incorporating chloroquine in niosomes biophysical performance, as well as the effect of non-ionic surfactant composition and protocol of incorporation in their biophysical performance. An exhaustive comparative evaluation of three niosome formulations differing in these parameters was performed, which included the analysis of their thermal stability, rheological behavior, mean particle size, dispersity, zeta potential, morphology, membrane packing capacity, affinity to bind DNA, ability to release and protect the genetic material, buffering capacity and ability to escape from artificially synthesized lysosomes. Finally, in vitro biological studies were, also, performed in order to determine the compatibility of the formulations with biological systems, their transfection efficiency and transgene expression. Results revealed that the incorporation of chloroquine in niosome formulations improved their biophysical properties and the transfection efficiency, while the substitution of one of the non-ionic surfactants and the phase of addition resulted in less biophysical variations. Of note, the present work provides several biophysical parameters and characterization strategies that could be used as gold standard for gene therapy nanosystems evaluation., Authors wish to thank: ICTS “NANBIOSIS”, specifically the Drug Formulation Unit (U10) of the CIBER in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) for the intellectual and technical assistance; SGIker (UPV/EHU) for technical and human support; the Department of Education, University and Research of the Basque Country Government (Consolidated Groups, IT907-16); the Spanish Ministry of Science and Innovation (Grants PID2019-106199RB-C21 and RTI2018-099985-B-I00); also the support of CIBER of Respiratory Diseases (CIBERES-ISCIII) and the Cystic Fibrosis Association of the Basque Country. M.S.-R. thanks the University of the Basque Country (UPV/EHU) for the granted pre-doctoral fellowship (PIF17/79). I.V.-B. thanks the University of the Basque Country (UPV/EHU) for the granted postdoctoral fellowship (call for the Specialization of Doctor Researcher Personnel of the UPV/EHU, grant reference: ESPDOC19/47)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A novel gene delivery approach to face cystic fibrosis by non-viral vectors based on niocarbosomes

  • Maldonado, Iván
  • Gallego, Idoia
  • Enriquez-Rodriguez, Lucia
  • Iturrospe, Amaia
  • Arbe, Arantxa
  • Mashal, Mohamed
  • Attia, Noha
  • Puras, Gustavo
  • Pedraz, José Luis
Non-viral vectors are a promising approach to address genetic-based diseases, such as cystic fibrosis (CF), due to their safety profile and lower production costs compared to viral vectors. This study includes the development of conventional niosomes using the oil-in-water (o/w) emulsion technique, which were based on 2,3-di(tetradecyloxy)propan-1-amine (DTPA) cationic lipid and polysorbate 85 as a non-ionic surfactant. Additionally, novel niosomes referred to as niocarbosomes were developed incorporating carboxyl-functionalised single-walled carbon nanotubes (SWNT-COOH) as a helper component. The physicochemical properties of formulations and their complexes obtained upon the addition of genetic material, referred to as nioplexes and niocarboplexes respectively, were thoroughly examined using transmission electron microscopy (TEM), dynamic light scattering (DLS), and small-angle X-ray scattering (SAXS) techniques. Furthermore, the formation of protein corona around the non-viral vectors was investigated upon exposure to human blood plasma. Niocarbosomes complexed with pEGFP reporter gene transfected around 26% of treated cells mainly via the lipid rafts pathway, with a cell viability rate of 85%. Next, these niocarbosomes were complexed with a therapeutic plasmid coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein (pGM169) for CF treatment. Treated cells showed a 65% increase in CFTR functionality compared to untreated cells, demonstrating the potential of niocarbosome non-viral gene delivery systems to face CF disease., This work was supported by the Basque Country Government (Consolidated Groups, IT1448-22). Authors also wish to thank the intellectual and technical assistance from the ICTS “NANBIOSIS,” more specifically by the Drug Formulation Unit (U10) of the CIBER in Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN) at the University of the Basque Country (UPV/EHU). I.M. thanks the Spanish Ministry of science and innovation (Grant PID2019-106199RB-C21) predoctoral grant PRE2020-092307. L.E.R. thanks the Basque Country Government for the granted pre-doctoral fellowship (PRE_2022_1_0042). N.A. and M.M acknowledge the Spanish Ministry of Universities and the European Union-Next Generation EU for the Margarita Salas grant (MARSA21/98 and MARSA21/97, respectively) at the University of the Basque Country (UPV/EHU). A. I. and A. A. acknowledge the Grant PID2021-123438NB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”, Grant TED2021-130107A-I00 funded by MCIN/AEI/10.13039/501100011033 and Unión Europea “NextGenerationEU/PRTR”, This work benefited from the use of the SasView application, originally developed under NSF award DMR-0520547., SasView contains code developed with funding from the European Union’s Horizon 2020 research and innovation programme under the SINE2020 project, grant agreement No 654000., Peer reviewed